RxDoctor Payments Data

Sumona Bhattacharya

Gastroenterology · Washington, DCNPI 1598210973

Payments from drug & device makers

What this record shows

This record is dominated by grants: $80,000 of the $86,966 with a category attached, or 92.0%. Pfizer accounts for 92.7% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2022 at $40,434 and has fallen 95.1% since, to $1,964 in 2025. Among gastroenterology clinicians in DC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$86,966in general payments, 2019–2025

Across 171 payments — averaging $508.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$81K
  • Janssen Scientific Affairs, LLC$3K
  • AbbVie$1K
  • Johnson & Johnson$633
  • Bristol Myers Squibb$324
  • Takeda Pharmaceuticals U.S.A., Inc.$283
  • plus $1K from 16 others

What the payments were for

  • Consulting fees$1,6052%
  • Grants$80,00092%
  • Food & beverage$5,3006%
  • Education$610%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$86,966 in reported general payments places this provider in the 90th percentile of 77 gastroenterology providers in District of Columbia.

See all gastroenterology providers in District of Columbia

Medicare billing

Part B allowed, 2024
$374,374
Medicare patients
140
Services billed
17,522

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl20$310
Pantoprazole Sodium24$290
Omeprazole18$271
Famotidine20$164

Paid to pharmacies, not to this prescriber.

Other gastroenterology in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →